Trials / Terminated
TerminatedNCT02142725
Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis
Randomized, Double-blind, Double-dummy, Placebo-controlled, Phase III Clinical Trial on the Efficacy and Safety of a 12-weeks add-on Treatment With LT 02 vs. Placebo in Patients With Ulcerative Colitis Refractory to Standard Treatment With Mesalamine
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 468 (actual)
- Sponsor
- Dr. Falk Pharma GmbH · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare two different dosing regimens of phosphatidylcholine versus placebo for the induction of remission in ulcerative colitis patients non-responsive to standard mesalamine treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LT-02 | four times per day |
| DRUG | LT-02 | two times per day |
| DRUG | Placebo | four times per day |
Timeline
- Start date
- 2014-07-21
- Primary completion
- 2016-11-11
- Completion
- 2016-12-16
- First posted
- 2014-05-20
- Last updated
- 2017-02-09
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02142725. Inclusion in this directory is not an endorsement.